Dr. Neal D. Shore
/content/dam/asset-migration/headshots/us-doctor-headshots/US_Urology_Head_shot_GA_Neal_D_Shore.jpg

Neal D. Shore

Neal D. Shore
Neal D.
Shore
MD, FACS
US CMO of Urology and Surgery

Languages spoken

English

Expert in

Urology, Urologic Surgery

Interested in

Prostate and Bladder Cancer, Erectile Dysfunction, Voiding Disorders, BPH Trials

Overview

Centers

Dr. Neal Shore graduated both Duke University and Duke University Medical School. He completed his general surgery/urology residence at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center.

He is the Medical Director, for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 400 clinical trials, focusing mainly for GU Oncology indications.

He is the Chief Medical Officer, Surgery/Urology, for GenesisCare, US. He has more than 250 peer reviewed publications and numerous book chapters. He serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee.

He is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and also serves as Editor, Everyday Urology-Oncology.

He is a Fellow of the American College of Surgeons.  

Education

Universities
Residencies
  • Duke University, BA, Public Policy Sciences, Durham, NC
  • Duke University School of Medicine, Durham, NC
  • The New York Hospital, Cornell Medical Center, General Surgery, New York, NY
  • The New York Hospital, Cornell Medical Center, Chief Resident, Urology, New York, NY

Professional association

Publications

  • Androgen Deprivation Therapy in Prostate Cancer: Balancing the Risks and Benefits. View presentation
  • Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. View presentation
  • Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. View presentation
  • Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. View publication
  • Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer. View publication
  • The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. View publication
  • Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. View publication
  • Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36. View publication
  • Hereditary cancer risk assessment and genetic testing in the community urology practice setting. View publication
  • Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. View publication
  • The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. View publication
  • Improving access to oncology publications for advocates and people with cancer. View publication
  • Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. View publication
  • Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? View publication
  • Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer. View publication
  • Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). View publication
  • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. View publication
  • Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. View publication
  • Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. View publication
  • Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. View publication
  • IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER. View publication
  • Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. View publication
  • Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. View publication
  • Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. View publication
  • Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases. View publication
  • A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer View publication
  • Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]. View publication
  • Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply View publication
  • Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity? View publication
  • Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams. View publication
  • Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. View publication
  • Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer. View publication
  • Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. View publication
  • Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. View publication
  • An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. View publication
  • Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. View publication
  • Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). View publication
  • Low-grade prostate cancer should still be labelled cancer. View publication
  • Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer. View publication
  • Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. View publication
  • Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. View publication

Presentations

DD-MVAC is the new SOC
Neal D. Shore, 2021, OncLive
View presentation

PSMA – RLT is here
Neal D. Shore, 2021, OncLive
View presentation

Is triplet therapy the new SOC?
Neal D. Shore, 2021, OncLive
View presentation

HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Neal D. Shore, 2020, ASCO Annual Meeting

Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Neal D. Shore, 2020, ASCO Annual Meeting

Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).
Neal D. Shore, 2020, ASCO Annual Meeting

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
Neal D. Shore, 2020, ASCO Annual Meeting

DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab Plus Enzalutamide in Abiraterone-Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Updated Results from Keynote-365 Cohort C
Yu, EY, P Fong, JM Piulats, L Appleman, H Conter, S Feyerabend, N Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS de Bonno, A Kam, U Emmenegger, H Wu, C Poehlein, and W Berry, 2020, American Urological Association Annual Meeting

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388)
Vaishampayan, UN, EJ De Wit, ND Shore, R Dreicer, DJ George, RV Boccia, BD Curti, L Geczi, T Csõszi, and NJ Vogelzang, 2020, Genitourinary Cancers Symposium

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
Taplin, M-E, M Gleave, CP Evans, E Efstathiou, PW Kantoff, A Ross, ND Shore, A Briganti, BA Hadaschik, A Heidenreich, OB Rooney, SK Tian, L Wetherhold, W Xu, S Cheng, SD Brookman-May, A Lopez-Gitlitz, and AS Kibel, 2020, Genitourinary Cancers Symposium

Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Shore, ND, OA Sartor, CN Sternberg, F Saad, BF Tombal, K Miller, J Kalinovsky, X Jiao, K Tangirala, and CS Higano, 2020, Genitourinary Cancers Symposium

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Shore, ND, R Patel, R Xu, PS Multani, Michael J. Morris, and W Abida, 2020, Genitourinary Cancers Symposium

Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC)
Shore, ND, L Oliver, I Shui, A Gayle, OY Wong, J Kim, S Payne, and SR Ghate, 2020, Genitourinary Cancers Symposium

Integrating comprehensive genomic profiling into the clinical management of prostate cancer patients: A single institution community practice experience
Shore, ND, J Haberberger, EA Severson, P Sathyan, P Reddy, and SH Ramkissoon, 2020, Genitourinary Cancers Symposium

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
Shore, ND, Mostefa Bennamoun, R Ratta, JM Piulats, B Li, C Schloss, and K Fizazi, 2020, Genitourinary Cancers Symposium

HERO Phase 3 Trial: Results Comparing Relugoliz, an Oral GNRH Receptor Antagonist, vs Leuprolide Acetate for Advanced Prostate Cancer
Shore, N, F Saad, M Cookson, DJ George, DR Saltzstein, R Tutrone, H Akaza, A Bossi, D van Veenhuyzen, B Selby, X Fan, V Kang, J Walling, and B Tombal, 2020, American Urological Association Annual Meeting

Phase 3 Results of Vicinium in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Shore, N, M O’Donnell, T Keane, MAS Jewett, GS Kulkarni, R Dickstein, F Wolk, C Dunshee, L Belkoff, RL Dillon, J Cizeau, and W Kassouf, 2020, American Urological Association Annual Meeting

Impact of Baseline Disease Volume and Prior Docetaxel Therapy on Prostate-Specific Antigen-Related Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide Plus Androgen Deprivation Therapy
Shore, N, ED Crawford, RZ Szmulewitz, D Petrylak, J Holzbeierlein, A Villers, A Azad, A Alcaraz, B Alekseev, T Iguchi, F Gomez-Veiga, B Rosbrook, B Baron, GP Haas, A Stenzl, and AJ Armstrong, 2020, American Urological Association Annual Meeting

Prostate Cancer Active Surveillance Quality in Large Community Urology Practices
Shelton, J, E Wood, T Paivanas, P Buffington, S Ruyle, E Cohen, R Natale, B Mehlhaff, R Suh, T Bradford, A Koo, L Kwan, and N Shore, 2020, American Urological Association Annual Meeting

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Saad, F, KN Chi, ND Shore, JN Graff, EM Posadas, BM Espina, E Zhu, A Hazra, B Bradic, S Cheng, V Hayreh, and A Rezazadeh, 2020, Genitourinary Cancers Symposium

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)
Ross, A, AJ Armstrong, Christopher M Pieczonka, JL Bailen, RF Tutrone, MR Cooperberg, CP Pavlovich, JF Renzulli, H Haynes, NA Sheikh, and ND Shore, 2020, Genitourinary Cancers Symposium

The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE
Petrylak, DP, ES Antonarakis, H Kandadi, L Fong, RS Lance, T Vu, NA Sheikh, ND Shore, and CG Drake, 2020, Genitourinary Cancers Symposium

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience
Hussain, MHA, J Mateo, SK Sandhu, K Fizazi, F Saad, ND Shore, D Olmos, C Corcoran, C Sibilla, A Kohlmann, CA Adelman, JA Elvin, CD Goessl, J Burgents, and JS De Bono, 2020, Genitourinary Cancers Symposium

Can TURBT be Avoided? Primary Chemoablation with a Reverse Thermal Gel Containing Mitomycin (UGN-102) in Patients with Low Grade Intermediate Non-Muscle Invasive Bladder Cancer
Huang, W, K Chevli, A Trainer, A Smith, D Saltzstein, Y Ehrlich, B Friiedman, R D’Anna, D Morris, B Hu, M Tyson, A Sankin, M Kates, J Linehan, D Scherr, S Kester, M Verni, K Chemie, L Karsch, A Cinman, E Seltzer, N Gabai, R Kirshoff, M Schoenberg, J Raman, and N Shore, 2020, American Urological Association Annual Meeting

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
Higano, CS, F Saad, AO Sartor, K Miller, P Conti, DJ George, CN Sternberg, ND Shore, JP Sade, J Bellmunt, MR Smith, C Logothetis, F Verholen, J Kalinovsky, I Bayh, and BF Tombal, 2020, Genitourinary Cancers Symposium

Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
Galsky, MD, A Necchi, ND Shore, F Witjes, K Nam, E Sbar, B Homet Moreno, and ER Plimack, 2020, Genitourinary Cancers Symposium

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
De Bono, JS, K Fizazi, F Saad, ND Shore, G Roubaud, M Ozguroglu, N Penel, N Matsubara, N Mehra, G Procopio, MP Kolinsky, K Nishimura, S Feyerabend, JY Joung, NJ Vogelzang, MA Carducci, J Kang, CH Poehlein, W Wu, and MHA Hussain, 2020, Genitourinary Cancers Symposium

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, WR, PCC Fong, JM Piulats, LJ Appleman, HJ Conter, S Feyerabend, ND Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS De Bono, AE Kam, U Emmenegger, Helen Wu, Charles Schloss, Christian Heinrich Poehlein, and Evan Y. Yu, 2020, Genitourinary Cancers Symposium

TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC)
Agarwal, N, ND Shore, C Dunshee, LI Karsh, A Azad, AP Fay, J Carles, B Sullivan, N Di Santo, M Elmeliegy, X Lin, RGW Quek, A Czibere, and K Fizazi, 2020, Genitourinary Cancers Symposium

Lower ut symptoms due to benign prostatic hyperplasia
Shore, N.D.,

Z120920141
Francisco A. Myslicki, Jesse Shulman, Sharon Salenius, Neal Shore, Constantine Mantz, Eduardo Fernandez, Steven E. Finkelstein, 2015, ARS

Z050320161
Neal D. Shore, 2016, E-Cancer TV

mshoreurotoday
Neal D. Shore, 2017, LUGPA

mshore31618
Neal D. Shore, 2018, Urology Today

61520157
Myslicki FA, Salenius SA, Shore ND, Mantz CA, Fernandez E, Finkelstein SE, 2015, ACRO Annual Meeting

In the media

Low-grade prostate cancer should still be labelled cancer

September 9, 2022

View publication

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

September 13, 2022

View article 

LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

November 9, 2022

View video

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

2022

View video

Therapeutic Sequencing in View of Advanced Prostate Cancer Biology

2022

View article

Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer

February 10, 2023

View article

Low-grade prostate cancer should still be labelled cancer

September 9, 2022

View article

Thank you for submitting.

We will be in touch within 24 hours.

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

Our staff will provide answers to your questions within 24 hours. Otherwise, if you have a medical emergency please call 911.

*Indicates a required field